Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.05.007 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2026. Verfasst von Elise Jirovec und 23 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Adenoviridae, Oncolytic Viruses, Neoplasms, Oncolytic Virotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Finland, Cancer Foundation Finland, Sigrid Jusélius Foundation.
Abstract (Originalsprache)
TILT-123 (Ad5/3-E2F-d24-hTNFα-IRES-hIL2, igrelimogene litadenorepvec) is a chimeric oncolytic adenovirus engineered to selectively replicate in tumor cells and express tumor necrosis factor (TNF) and interleukin-2 (IL-2). While oncolytic viruses are commonly administered intratumorally, this approach often restricts practical applicability. Intravenous delivery is less invasive and offers a more practical alternative; however, systemic immune barriers challenge effective tumor targeting. In a cohort of a phase 1 clinical trial, six patients with advanced solid tumors who had exhausted standard treatments received two intravenous doses of TILT-123 (split-dose), per treatment day across seven cycles. Safety was the primary objective, while efficacy outcomes were exploratory and assessed using positron emission tomography/-computed tomography (PET/CT) imaging, along with overall survival. Split-dosing was safe, with chills, fever, fatigue, and lymphocyte reduction being the most common treatment-related events. In imaging, the disease control rate was 83.3% according to PET criteria and 33.3% by RECIST 1.1. The median overall survival was 198 days. Split-dosing increased the area under the curve of TILT-123 and amplified systemic cytokine responses. Proteomic analysis of serum and neutralizing antibody profiling indicated that enhanced humoral immune activity was associated with shorter overall survival. Post-treatment biopsies confirmed virus presence and alterations in immune cell composition. These findings support further evaluation of intravenous TILT-123 administration in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland.
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; TILT Biotherapeutics Oy, Helsinki, Finland.
- Docrates Cancer Center, Helsinki, Finland.
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland; Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland.
- Research Programs in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, Helsinki Institute Sciences, University of Helsinki, Helsinki, Finland; Cl…
Förderung
- Research Council of Finland
- Cancer Foundation Finland
- Sigrid Jusélius Foundation
- Finnish Red Cross Blood Service
- Jane and Aatos Erkko Fundation
Zitieren
APA
Jirovec, E., Jalkanen, K. J., Quixabeira, D. C. A., Clubb, J. H. A., Alanko, T., Kudling, T. V., Arias, V., Pakola, S. A., Grönberg-Vähä-Koskela, S., van der Heijden, M., Färkkilä, A., Kononen, J., Sormunen, J., Kemppainen, J., Hellesuo, M., Haybout, L., Kistler, C., Sorsa, S., Havunen, R., …, & Hemminki, A. (2026). Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.05.007
Vancouver
Jirovec E, Jalkanen KJ, Quixabeira DCA, Clubb JHA, Alanko T, Kudling TV, et al. Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.05.007
BibTeX
@article{Jirovec2026,
author = {Jirovec, Elise and Jalkanen, Katriina J and Quixabeira, Dafne C A and Clubb, James H A and Alanko, Tuomo and Kudling, Tatiana V and Arias, Victor and Pakola, Santeri A and Grönberg-Vähä-Koskela, Susanna and van der Heijden, Mirte and Färkkilä, Anniina and Kononen, Juha and Sormunen, Jorma and Kemppainen, Jukka and Hellesuo, Maria and Haybout, Lyna and Kistler, Claudia and Sorsa, Suvi and Havunen, Riikka and Santos, Joao M and Kanerva, Anna and Cervera-Carrascon, Victor and Hemminki, Otto and Hemminki, Akseli},
title = {Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.05.007}
}
EUVIMED